In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.
At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.
They range from skin conditions associated with sexually transmitted infections to acne to hair loss and removal for the alignment of appearance to gender identity.
People of color are more likely to develop atopic dermatitis and have more severe disease. Vtama, currently approved to treat plaque psoriasis, is being studied to treat patients with atopic dermatitis.
The FDA has approved Wegovy for reducing cardiovascular risks in people who are obese or overweights. The agency approved new biosimilars that reference Actema, Prolia and Xgeva. Additionally, the FDA plans to hold advisory committee meeting for donanemab in Alzheimer’s disease.
A content analysis of 75 TikTok videos showed that most have positive information about the oral acne medication, which was previously sold under the brand name Accutane. But larger majority (77%) of the videos have negative information about isotretinoin, and a large percentage of those videos give the positive effects only a passing mention, if any at all.
At the webinar event, held by the Pharmacy Benefit Management Institute, industry leaders discussed the patient’s journey and the latest trends in the oncology market.
The results of this week’s poll about health insurance coverage of GLP-1s for weight loss.
In a discussion with Managed Healthcare Executive, Jonathan I. Silverberg, M.D., Ph.D., M.P.H., an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, discussed the concept of "atopic march."
There was no mention in President Joseph Biden's Statue of the Union Address about PBM reform, which has garnered a lot of interest from patient advocates and Congress over the last year.
The annual meeting will run through Tuesday.
John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
It was found in a recent study that the updated Moderna, Pfizer-BioNTech and Novavax COVID-19 vaccines, when combined with antiviral treatments like nirmatrelvir and molnupiravir, can significantly decrease the chances of hospitalization and death from current COVID-19 variants.
These researchers want to normalize menopause before treating symptoms with medicine.
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
There was only a total of 58 cases in 2023.
Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
By embracing change, leveraging emerging trends and prioritizing patient-centered care, organizations and individuals can find opportunities for growth and innovation in the post-pandemic era.
Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.
Women experiencing high levels of poverty and those in impoverished rural regions are less likely to get screened for breast cancer, find a new review of studies that have assessed social determinants of health.
The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.
Hospitals and healthcare software developers are adjusting to a world in which blocking healthcare data will come with potentially stiff penalties under rules proposed by the Office of the National Coordinator for Health Information Technology (ONC).
Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Advances in MS disease management have included the emergence of monoclonal antibodies as effective disease-modifying therapies (DMTs) for MS. FDA-approved treatments include Tysabri (natalizumab), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), and Kesimpta (ofatumumab).
ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”
CivicaScript, a generic medication manufacturer, is modeling itself as public utility. It launched its first product, abiraterone 250 mg tablets, late last year and is gearing up to make its own low-cost insulin.
A new study points to disparities for patients in respiratory failure, which can have dire consequences. The lead researchers talk about the implications.
FDA has expanded the indication for Biktarvy for those with resistant HIV, granted full approval to Rybrevant and approved Simlandi, the third interchangeable Humira biosimilar. The regulatory agency has also set action dates for sxatilimab in graft-versus-host disease, tislelizumab in stomach cancer and a second indication for Epkinly.
